La chaîne d'options affiche les données clés des options sur actions de CTS à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour CTS..

CTS (NYSE:CTS) Stock, Chaîne d'Options

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.

CTS Corp

CONVERGE TECH SLTN CORP by Converge Technology Solutions Corporation

Converge Technology Solutions Corp

Cognizant Technology Solutions Corporation - Class A Common Stock

Cognizant Technology Solutions Corp

Cartesi - United States Dollar

CytoSorbents Corp

Cactus Acquisition Corp 1 Ltd Units (1 Ord Share Class A & 1/2 War)

Cactus Acquisition Corp 1 Ltd

Cactus Acquisition Corp 1 Ltd Warrants(17/08/2028)

WIIM

ADEA

AEIS

AEVA

AGYS

AIOT

ALAB

ALAR

ALGM

AMPG

AMPL

ARLO

ASGN

ASTI

ATOM

BASE

BBAI

BELFA

BELFB

BIGC

BLBX

BLZE

BTCT

BZAI

CAMT

CCCS

CCRD

CEVA

CGNX

CLMB

CMPO

COHU

CRDO

CRNC

CRSR

CSIQ

CSPI

CTSH

CWAN

CXDO

DAKT

DAVA

DCBO

DGII

DIOD

DJCO

DMRC

DOCN

DOMO

EBON

EPAM

ETWO

EVCM

EVLV

EXFY

FARO

FCUV

FLEX

FSLR

GDYN

GRRR

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IDCC

INFA

INFY

INGM

INSG

IONQ

IPGP

ITRI

JAMF

Shares of broader tech companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

<p><strong>CTS</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 08:00 AM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>CTS missed estimated earnings by -2.0%, reporting an EPS of $0.53 versus an estimate of $0.54.</p>
<p>Revenue was up $2.74 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company beat on EPS by $0.06, resulting in a 2.0% increase change in the share price the following day.</p>
<p>Here's a look at CTS's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.57</td>
<td>0.53</td>
<td>0.41</td>
<td>0.46</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.63</td>
<td>0.54</td>
<td>0.47</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>132.48M</td>
<td>133.38M</td>
<td>126.75M</td>
<td>124.51M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>132.42M</td>
<td>130.16M</td>
<td>125.75M</td>
<td>124.69M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>CTS management provided guidance for FY 2025, expecting earnings between $2.2 and $2.35 per share.</p>
<p>To track all earnings releases for CTS <a href="https://www.benzinga.com/quote/CTS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

CTS Earnings Analysis: Q4 Recap

<p>CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) reported quarterly earnings of $0.53 per share which missed the analyst consensus estimate of $0.59 by 10.17 percent. This is a 12.77 percent increase over earnings of $0.47 per share from the same period last year.  The company reported quarterly sales of $127.435 million which missed the analyst consensus estimate of $132.804 million by 4.04 percent.  This is a 2.20 percent increase over sales of $124.694 million the same period last year.</p>


Earnings Misses

News

CTS Q4 2024 Adj. EPS $0.53 Misses $0.59 Estimate, Sales $127.435M Miss $132.804M Estimate

ALGT

AMCR

AMGN

APAM

ARMK

ATEN

ATKR

AUDC

AVNW

AXTA

AZEK

AZPN

BALL

BERY

COLM

CRUS

CVRX

EGHT

ENPH

ENVA

FICO

FLNG

FOXA

GBDC

GOOG

GOOGL

HLNE

HUBB

ICHR

IESC

INGR

INMD

INNV

INTA

JKHY

JNPR

KLIC

KTCC

LANC

LARK

LUMN

MDLZ

MLAB

MPLX

MRCY

MSGS

MTCH

MUFG

OCSL

OSCR

PINC

PYPL

RACE

Earnings Scheduled For February 4, 2025

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

Comments

CTS

CTS (CTS) Options

CTS (NYSE:CTS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL